Abstract:Background: Acute ischemic stroke (AIS) is an atherothrombotic disease. Trimethylamine-N-oxide (TMAO), a gut microbiota-dependent metabolite, has been shown to be proatherogenic and prothrombotic. However, the involvement of TMAO in AIS remains unclear. This study aimed to observe the dynamic changes of TMAO in AIS patients and identify the prognostic value of TMAO for major ischemic events and unfavorable functional outcomes. Methods: This study included 204 AIS patients and 108 healthy controls. Blood samples for TMAO analyses were drawn at admission, 2 and 7 days of admission. Logistic regression models and receiver operating characteristic curves were established to identify associations between TMAO levels and major ischemic events (ischemic stroke, myocardial infarction, or death from an ischemic vascular event), as well as unfavorable functional outcomes (modified Rankin Scale score >= 3), at 90 days and 12 months. Results: TMAO levels showed no significant changes before and within 24 h of AIS treatment (at admission) but decreased significantly thereafter. Elevated log(2)-transformed baseline TMAO levels were associated with increased risks of 90-day [odds ratio (OR), 2.62; 95% confidence interval (CI), 1.55-4.45; p < 0.001] and 12-month (OR, 3.59; 95% CI, 2.12-6.09; p < 0.001) major ischemic events, as well as 90-day (OR, 2.89; 95% CI, 1.46-5.71; p = 0.002) and 12-month (OR, 2.58; 95% CI, 1.50-4.46; p = 0.001) unfavorable functional outcomes, after adjustments for confounding factors. The areas under curve of baseline TMAO levels for predicting 90-day and 12-month major ischemic events were 0.72 (95% CI, 0.61-0.83; p < 0.001) and 0.76 (95% CI, 0.66-0.85; p < 0.001). Baseline TMAO levels improved the prognostic accuracy of conventional risk factors, National Institutes of Health Stroke Scale (NIHSS) score and N-terminal B-type natriuretic peptide (NT-proBNP) level. Conclusions: TMAO levels decreased with time since stroke onset. Elevated TMAO levels at an earlier period portended poor stroke outcomes, broadening the potential clinical utility of TMAO as an independent prognostic marker and therapeutic target.

Trimethylamine N-Oxide in Heart Failure: A Meta-Analysis of Prognostic Value

Dynamic Changes and Prognostic Value of Gut Microbiota-Dependent Trimethylamine-N-Oxide in Acute Ischemic Stroke.

Association between trimethylamine N-oxide and prognosis of patients with myocardial infarction: a meta-analysis

Trimethylamine N-Oxide Levels Are Associated with Severe Aortic Stenosis and Predict Long-Term Adverse Outcome

The correlation between plasma trimethylamine N-oxide level and heart failure classification in northern Chinese patients

Role of Trimethylamine N-Oxide in Heart Failure

Trimethylamine oxide: a potential target for heart failure therapy

FMO3-TMAO axis modulates the clinical outcome in chronic heart-failure patients with reduced ejection fraction: evidence from an Asian population

The association between the gut microbiota metabolite trimethylamine N-oxide and heart failure

Association of trimethylamine N -Oxide with cardiovascular and all-cause mortality in hemodialysis patients

Trimethyllysine, a Trimethylamine N-oxide Precursor, Predicts the Presence, Severity, and Prognosis of Heart Failure

Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target

Abstract 12622: Gut-microbiota-derived Trimethylamine-N-oxide levels and Risk of Major Adverse Cardiovascular Events: A Systematic Review and Meta-analysis of Prospective Cohort Studies

Effect of TMAO on the incidence and prognosis of cerebral infarction: a systematic review and meta-analysis

Trimethylamine N-Oxide and Risk of Cardiovascular Disease and Mortality

Trimethylamine N-oxide is associated with coronary atherosclerotic burden in non-ST-segment myocardial infarction patients: SZ-NSTEMI prospective cohort study

High-circulating Gut Microbiota-Dependent Metabolite Trimethylamine N-oxide is Associated with Poor Prognosis in Pulmonary Arterial Hypertension.

The Gut Microbial Metabolite Trimethylamine <i>N</i>-Oxide and Hypertension Risk: A Systematic Review and Dose-Response Meta-analysis

Gut microbiota-dependent metabolite trimethylamine N-oxide (TMAO) and cardiovascular risk in patients with suspected functionally relevant coronary artery disease (fCAD)

Trimethylamine N-oxide predicts cardiovascular events in coronary artery disease patients with diabetes mellitus: a prospective cohort study

Prognostic Value of Plasma Trimethylamine N-Oxide Levels in Patients with Acute Ischemic Stroke